Oragenics (LTS:0A64) Total Stockholders Equity : $3.08 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Oragenics Total Stockholders Equity?

Oragenics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $3.08 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Oragenics's Book Value per Share for the quarter that ended in Sep. 2024 was $0.16. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Oragenics's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.17.

Oragenics Total Stockholders Equity Historical Data

The historical data trend for Oragenics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Total Stockholders Equity Chart

Oragenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

17.23

16.85

26.49

13.01

3.17

Oragenics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															6.50	3.17	2.63	1.33	3.08

Oragenics (LTS:0A64) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Oragenics's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.078	-	1.593)	/	9.38755
	=	0.16

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Oragenics's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.519	+	0)	/	3.078
	=	0.17

Oragenics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Oragenics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oragenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (LTS:0A64) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

OGEN:USA

Address

1990 Main Street, Suite 750, Tampa, FL, USA, 34236

Website

https://www.oragenics.com

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Oragenics Headlines

No Headlines